Eysuvis 0.25% (2.5 mg/mL) ophthalmic suspension Images
Generic Name: loteprednol
This medication has been identified as Eysuvis 0.25% (2.5 mg/mL) ophthalmic suspension. It is supplied by Kala Pharmaceuticals, Inc.
Eysuvis is used in the treatment of Dry Eye Disease and belongs to the drug class ophthalmic steroids. Risk cannot be ruled out during pregnancy. Eysuvis 0.25% (2.5 mg/mL) ophthalmic suspension is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Eysuvis
- Generic Name
- loteprednol
- Strength
- 0.25% (2.5 mg/mL) ophthalmic suspension
- Availability
- Prescription only
- Drug Class
- Ophthalmic steroids
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Kala Pharmaceuticals, Inc.
- National Drug Code (NDC)
- 71571-0333
See also:
Restasis
Restasis is used to treat chronic dry eye that may be caused by inflammation. Learn about side ...
Chantix
Chantix is a smoking cessation medicine used with behavior modification and counseling to help you ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Xiidra
Xiidra (lifitegrast 5%) is an eye drop solution that is used twice daily in each eye to treat the ...
Miebo
Miebo (perfluorohexyloctane) is used to treat the signs and symptoms of dry eye disease. Includes ...
Cequa
Cequa (cyclosporine ophthalmic) is a prescription eye drop used to treat chronic dry eye from ...
Lotemax
Lotemax and Lotemax SM (loteprednol etabonate) are corticosteroid medications used to help treat ...
More about Eysuvis (loteprednol ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (8)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: ophthalmic steroids
- Breastfeeding
- En español
Patient resources
Other brands
Lotemax, Alrex, Lotemax SM, Inveltys
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.